Vydané akcie společnosti Apellis Pharmaceuticals Inc

Jaká je hodnota metriky Vydané akcie společnosti Apellis Pharmaceuticals Inc?

Hodnota metriky Vydané akcie společnosti Apellis Pharmaceuticals Inc je 121.766M

Jaká je definice metriky Vydané akcie?



Vydané akcie (Shares outstanding) je počet všech akcií společnosti nebo finančních aktiv, které byly autorizované, vydané a koupené investory a jsou jimi vlastněné.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Vydané akcie společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Apellis Pharmaceuticals Inc

Čemu se věnuje společnost Apellis Pharmaceuticals Inc?

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.

Firmy s metrikou vydané akcie podobnou společnosti Apellis Pharmaceuticals Inc